Amgen (AMGN) Earns News Sentiment Score of 0.25
News coverage about Amgen (NASDAQ:AMGN) has trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amgen earned a news impact score of 0.25 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 46.033332766099 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news articles that may have impacted Accern’s analysis:
- Amgen Gets Positive CHMP Opinion to Expand Nplate’s Label (nasdaq.com)
- ETFs with exposure to Amgen, Inc. : November 13, 2017 (finance.yahoo.com)
- New Analyses Presented At AHA 2017 Show Repatha® (evolocumab) Significantly Reduced Cardiovascular Events In Patients With Peripheral Artery Disease And In Patients With A History Of Heart Attacks (finance.yahoo.com)
- Earnings Momentum Restrict Amgen (AMGN) Rating (investorplace.com)
- Read This Before Buying Amgen Inc (AMGN) For Its Upcoming $1.15 Dividend (finance.yahoo.com)
Several equities research analysts recently issued reports on the stock. BMO Capital Markets reissued a “hold” rating and issued a $199.00 target price on shares of Amgen in a research report on Monday, September 25th. Credit Suisse Group reaffirmed a “neutral” rating and set a $186.00 price target (up from $177.00) on shares of Amgen in a research report on Friday, September 29th. Cann reiterated a “buy” rating and set a $203.00 price objective (up previously from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. BidaskClub lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Mizuho reiterated a “buy” rating and set a $198.00 price objective (up previously from $183.00) on shares of Amgen in a research note on Thursday, September 28th. Thirteen investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $190.03.
Shares of Amgen (NASDAQ:AMGN) traded down $2.37 during mid-day trading on Tuesday, hitting $169.13. The stock had a trading volume of 343,849 shares, compared to its average volume of 3,249,994. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $124,490.00, a PE ratio of 13.70, a PEG ratio of 2.50 and a beta of 1.37. Amgen has a 12 month low of $138.83 and a 12 month high of $191.10.
Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business’s revenue for the quarter was down .7% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.02 earnings per share. equities research analysts forecast that Amgen will post 12.66 earnings per share for the current year.
Amgen declared that its Board of Directors has initiated a share buyback program on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Friday, November 17th will be issued a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 2.72%. The ex-dividend date is Thursday, November 16th. Amgen’s dividend payout ratio is 41.55%.
In other Amgen news, Director Carbonnel Francois De sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.
WARNING: “Amgen (AMGN) Earns News Sentiment Score of 0.25” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.watchlistnews.com/amgen-amgn-earns-news-sentiment-score-of-0-25/1702434.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.